InvestorsHub Logo
Followers 27
Posts 398
Boards Moderated 0
Alias Born 12/10/2015

Re: None

Thursday, 09/27/2018 6:48:21 PM

Thursday, September 27, 2018 6:48:21 PM

Post# of 470530
At CTAD, in addition to the late-breaking oral presentation on the 148wk Phase 2a data, Anavex will have a poster focused on the Phase 2b/3 clinical trial methodology:

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1, Michael Kornhauser BPharm1, Ella Modini BSc1, Harald Hampel, MD PhD2, Stephan Toutain MS3, Christopher Missling PhD3
1HammondCare Dementia Centre, NSW, Australia, 2Sorbonne University, Paris, France, 3Anavex Life Sciences Corp., New York, USA

Final program PDF can be downloaded here: http://www.ctad-alzheimer.com/program-0
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News